metaPreg - Fluvoxamine during pregnancy

Fluvoxamine updated on 10-20-2025

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	0.77 [0.48, 1.25]	0%	5 studies	116,016	519	not evaluable	ROB	-
Major congenital malformations	0.75 [0.45, 1.24]	0%	4 studies	74,781	481	not evaluable	ROB	-
Congenital heart defects	1.15 [0.49, 2.69]	0%	3 studies	8,651	414	not evaluable	ROB	-
Limb defects	0.83 [0.31, 2.23]	0%	2 studies		295	not evaluable	ROB	-
Nervous system anomalies	2.37 [0.75, 7.46]	0%	2 studies		295	not evaluable	ROB	-
6 non statistically significant endpoints reported in only one study
Maternal consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
2 non statistically significant endpoints reported in only one study
Neonatal disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Neonatal death (< 28 days of life)	-	-	0 study					-
1 non statistically significant endpoints reported in only one study
Long term consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
1 non statistically significant endpoints reported in only one study
Intrauterine deaths
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Early intrauterine deaths (< 22 weeks) / Spontaneous abortions	2.36 [0.94, 5.95]	0%	2 studies	5,134	9	not evaluable	ROB	-
Late intrauterine deaths (> 22 weeks) / Stillbirths	-	-	0 study					-
Neuro-developmental disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Cognitive developmental disorders/delay (3-6 years old)	-	-	0 study					-
2 non statistically significant endpoints reported in only one study